Bemnifosbuvir

Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM) . Bemnifosbuvir has pangenotypic antiviral activity[1][2][3].

Product Specifications

CAS Number

[1998705-64-8]

Product Name Alternative

AT-511

UNSPSC

12352005

Hazard Statement

H301

Target

HCV; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/at-511.html

Purity

99.00

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@](F)(C)[C@H](N2C3=NC(N)=NC(NC)=C3N=C2)O[C@@H]1CO[P@](OC4=CC=CC=C4)(N[C@@H](C)C(OC(C)C)=O)=O

Molecular Formula

C24H33FN7O7P

Molecular Weight

581.53

Precautions

H301

References & Citations

[1]Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15 (1) :e0227104.|[2]Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8; AAC.02479-20.|[3]Elina Berliba, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30;63 (12) :e01201-19.